Detalhe da pesquisa
1.
Renal Disturbances during and after Radioligand Therapy of Neuroendocrine Tumors-Extended Analysis of Potential Acute and Chronic Complications.
Int J Mol Sci
; 24(8)2023 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37108668
2.
Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE-A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center.
Cancers (Basel)
; 15(22)2023 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38001726
3.
Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.
Nucl Med Rev Cent East Eur
; 25(1): 54-61, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137938
4.
Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms.
Nutrients
; 15(1)2022 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36615845
5.
Carcinoid Heart Disease: How to Diagnose and Treat in 2020?
Clin Med Insights Cardiol
; 14: 1179546820968101, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33192110
6.
Recombinant Human Thyrotropin Worsens Renal Cortical Perfusion and Renal Function in Patients After Total Thyroidectomy Due to Differentiated Thyroid Cancer.
Thyroid
; 30(5): 653-660, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31964314